The Vision of the International Institute of Nano and Molecular Medicine (I2NM2)

MOspace/Manakin Repository

Breadcrumbs Navigation

The Vision of the International Institute of Nano and Molecular Medicine (I2NM2)

Please use this identifier to cite or link to this item:

[-] show simple item record Hawthorne, M. Frederick Lee, Mark W. Kueffer, Peter Fang, Li Yang, Shuo Jalisatgi, Satish S. Lewis, Michael R. Ruthengael, Varyanna 2010-02-23T16:18:45Z 2010-02-23T16:18:45Z 2010-02 eng
dc.description Nanoscience Poster Session en
dc.description.abstract The translational research effort in boron neutron capture therapy (BNCT) described below and recently initiated at the University of Missouri International Institute of Nano and Molecular Medicine and the University of Missouri Research Reactor would benefit from collaboration with a research group knowledgeable in modeling human tumors using small animal hosts and cellular biology as it relates to therapeutic results and the treatment of experimental data. The boron-10 (10B) isotope is unique among light elements for its high neutron cross-section and low inherent toxicity. When subjected to relatively benign thermal neutrons, the 10B nucleus undergoes a neutron capture reaction forming an excited 11B species. This unstable nucleus subsequently undergoes essentially instantaneous fission to release 2.4 MeV of kinetic energy in the form of a pair of 7Li3+ and 4He2+ ions, which are confined to the volume of about one cell. Therefore, preferential accumulation of 10B-containing structures within cancerous cells can lead to selective destruction of these cells. This process is more commonly known as Boron Neutron Capture Therapy (BNCT) for cancer. The key to the implementation of this potentially powerful and selective therapy is the delivery of at least 30 parts per million (ppm) of 10B within the tumor tissue while minimizing superfluous 10B within the surrounding healthy tissue. This difference in 10B concentration is often denoted through the boron concentration in tumor to boron concentration in blood ratio, with a higher ratio being preferable. Herein we describe the synthesis and results of biodistribution experiments with two nano-scale boron delivery agents: liposomes and oligomeric phosphate diesters (OPDs). Liposomes, containing both amphiphilic (KC2B9H11(CH2)15CH3, MAC) and hydrophilic (Na3B20H17NH3, TAC) components and ranging in diameter from 30 to 100 nm, showed tumor boron accumulations as high as 50 ppm and tumor to blood ratios over 8. OPDs, ranging in size from 1 to 5 nm in diameter, also exhibited preferential tumor accumulations of 30 ppm at tumor to blood ratios as high as 35 to 1. In both cases, liposomes and OPDs greatly outperformed currently available small boron-containing pharmaceuticals at the same injected dose of 10B. Studies in which OPDs were fluorescently labeled proved their localization within the cellular nucleus, increasing the relative efficacy of these species due to their proximity to the DNA target. In conclusion, both liposomes and OPDs show great promise as nano-sized delivery vehicles for BNCT. en
dc.language.iso en_US en
dc.relation.ispartof Abstracts (Missouri Regional Life Sciences Summit 2010) en
dc.subject boron neutron capture therapy en
dc.subject cancer therapy en
dc.subject liposomes en
dc.subject oligomeric phosphate diesters en
dc.subject.lcsh Boron-neutron capture therapy en
dc.subject.lcsh Liposomes en
dc.subject.lcsh Phosphodiesters en
dc.title The Vision of the International Institute of Nano and Molecular Medicine (I2NM2) en
dc.title.alternative Boron-Rich Nanoscale Delivery Agents for the Boron Neutron Capture Therapy of Cancer
dc.type Poster en
dc.contributor.meetingname Missouri Life Sciences Summit (2010: University of Missouri--Kansas City) en
dc.contributor.corporatename University of Missouri (System) en
dc.relation.ispartofcommunity University of Missouri System. Missouri Summits. Missouri Regional Life Sciences Summit 2010

This item appears in the following Collection(s)

[-] show simple item record